Physician profile
Tejas V Joshi
NPI 1932635091
$493,761.72
in general payments reported to CMS, 2019-2025
26 companies · $191K in 2025
The $191K reported for 2025 was more than what 98% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.96 · 2022: $6,475 · 2023: $114K · 2024: $182K · 2025: $191K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $347K · Travel and Lodging: $53K · Consulting Fee: $46K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $29K · Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $346,567.51 |
| Travel and Lodging | $53,016.83 |
| Consulting Fee | $45,567.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $29,350.00 |
| Food and Beverage | $12,687.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $185,779.77 | 2022-2025 | Epclusa, Livdelzi |
| Novo Nordisk INC | $84,298.58 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Madrigal Pharmaceuticals | $57,535.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55,239.56 | 2022-2025 | Xifaxan, Trulance |
| Echosens North America, INC. | $53,938.52 | 2022-2025 | Fibroscan, Fibroscan |
| Abbvie INC. | $28,469.15 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $23,775.37 | 2025 | Iqirvo |
| Wilson Cook Medical Incorporated | $2,500.00 | 2024 | Echotip Insight |
| Cook Medical LLC | $471.58 | 2023-2024 | Echotip, Echotip Insight |
| Genzyme Corporation | $317.05 | 2023-2025 | |
| Mirum Pharmaceuticals, INC. | $303.50 | 2025 | Livmarli |
| Janssen Biotech, INC. | $177.80 | 2024 | Tremfya, Stelara |
| Boston Scientific Corporation | $148.47 | 2024-2025 | Acquire, General - Therapies |
| Histosonics, INC. | $141.88 | 2025 | |
| Phathom Pharmaceuticals, INC. | $131.73 | 2024 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $127.63 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.70 | 2023 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $77.53 | 2023 | Terlivaz |
| Qol Medical, LLC | $44.40 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $38.40 | 2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $33.00 | 2025 | Dupixent |
| Ardelyx, INC. | $23.93 | 2025 | Ibsrela |
| Nevro Corp. | $22.61 | 2023 | Senza |
| Shield Therapeutics INC | $18.01 | 2024 | |
| Celgene Corporation | $15.59 | 2023 | Zeposia |
| Lilly USA, LLC | $14.12 | 2024 | Zepbound, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejas Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.